New rules are reshaping the telehealth market for GLP-1s like Ozempic and Wegovy, potentially impacting access to these drugs ...

AbbVie remains strong long-term performer, offering a solid dividend yield and robust revenue growth despite share price dips ...

Use of an investigational monoclonal antibody called bimagrumab added to semaglutide produced weight loss while preserving ...

Tirzepatide could result in net lifetime health care costs of more than $16 trillion in the U.S. if all people eligible to ...

For adults with obesity or overweight, tirzepatide-linked improvements in cardiometabolic risk factors are associated with the degree of weight reduction.

Three people share the hoops they've jumped through, financial strain they've endured and risks they've taken on in order to ...

Tirzepatide use vs placebo was associated with slower decline in eGFR among patients with prediabetes and obesity or ...

A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with ...

0602K + tirzepatide produced multi-faceted remodeling of adipose (fat) tissue, including reduced visceral-to-subcutaneous adipose tissue ratio (VAT:SAT), increased brown adipose tissue, and a ...

The study included 7881 patients: 6109 and 1772 received semaglutide and tirzepatide, respectively; 80.8% had low maintenance dosages.

PR Newswire GRAND RAPIDS, Mich., June 20, 2025 MPC-inhibitor 0602K shows significant preservation of lean mass & increased muscle function combined with tirzepatide in pre-clinical DIO models ...